Abstract:Id3 limits PD-1 expression and exuberant effector differentiation of Th1 cells, protecting them from PD-1-mediated suppression during GVHD Id3 reduces chromatin accessibility of transcription factors that drive T cell PD-1 transcription, differentiation and dysfunction Persisting alloreactive donor T cells in target tissues are a determinant of graft-versus-host disease (GVHD), but the transcriptional regulators that control the persistence and function of tissue-infiltrating T cells remain elusive. We demonstrate here that Id3, a DNA-binding inhibitor, is critical for sustaining T cell responses in GVHD target tissues in mice, including the liver and intestine. Id3 loss results in aberrantly expressed PD-1 in polyfunctional Th1 cells, decreased tissue-infiltrating PD-1 + polyfunctional Th1 cell numbers, impaired maintenance of liver TCF-1 + progenitor-like T cells, and inhibition of GVHD. PD-1 blockade restores the capacity of Id3-ablated donor T cells to mediate GVHD. Single-cell RNA-sequencing analysis revealed that Id3 loss leads to significantly decreased CD28- and PI3K/AKT-signaling activity in tissue-infiltrating polyfunctional Th1 cells, an indicator of active PD-1/PD-L1 effects. Id3 is also required for protecting CD8 + T cells from the PD-1 pathway-mediated suppression during GVHD. Genome-wide RNA-sequencing analysis reveals that Id3 represses transcription factors (e.g., Nfatc2 , Fos , Jun , Ets1 , Prdm1 ) that are critical for PD-1 transcription, exuberant effector differentiation, and IFN responses and dysfunction of activated T cells. Id3 achieves these effects by restraining the chromatin accessibility for these transcription factors. Id3 ablation in donor T cells preserved their graft-versus-tumor effects in mice undergoing allo-HSCT. Furthermore, CRIPSR/Cas9 knockout of ID3 in human CD19-directed CAR-T cells retained their anti-leukemia activity in NOD/SCID/IL2Rg −/− mice early after administration. These findings identify that ID3 is an important target to reduce GVHD, and gene-editing program of ID3 may have broad implications in T cell-based immunotherapy.

The transcription regulator ID3 maintains tumor-specific memory CD8+ T cells in draining lymph nodes during tumorigenesis

TRAF3 regulates the effector function of regulatory T cells and humoral immune responses.

Ubc13 maintains the suppressive function of regulatory T cells and prevents their conversion into effector-like T cells

Tissue-infiltrating Alloreactive T Cells Require Id3 to Deflect PD-1-mediated Immune Suppression during GVHD

Expression of Id3 represses exhaustion of anti-tumor CD8 T cells in liver cancer

The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets

FOXP3+ regulatory T cell perturbation mediated by the IFNγ-STAT1-IFITM3 feedback loop is essential for anti-tumor immunity

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

The Transcription Factor Zfp335 Promotes Differentiation and Persistence of Memory CD8+ T Cells by Regulating TCF-1

Id1 expression promotes T regulatory cell differentiation by facilitating TCR costimulation.

Precise Spatiotemporal Interruption of Regulatory T-cell-Mediated CD8(+) T-cell Suppression Leads to Tumor Immunity

The DNA-binding Inhibitor Id3 Regulates IL-9 Production in CD4 + T Cells

Transient Regulatory-T-cell Interruption Promotes Skin-Resident Memory T Cells Mediated Tumor Protection

NR4A1 transcriptionally regulates the differentiation of stem-like CD8+ T cells in the tumor microenvironment

Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity

ID1 expressing macrophages support cancer cell stemness and limit CD8+ T cell infiltration in colorectal cancer

STAT3-Mediated Promoter-Enhancer Interaction Up-Regulates Inhibitor of DNA Binding 1 (ID1) to Promote Colon Cancer Progression

Transcription factor 3 promotes migration and invasion potential and maintains cancer stemness by activating ID1 expression in esophageal squamous cell carcinoma.

Id2 epigenetically controls CD8 + T-cell exhaustion by disrupting the assembly of the Tcf3-LSD1 complex

Transcriptional heterogeneity in cancer-associated regulatory T cells is predictive of survival.

A Reservoir of Stem-Like CD8 T Cells in the Tumor-Draining Lymph Node Maintains the Ongoing Anti-Tumor Immune Response